Looking back, to the future of circulating tumor cells

Friedlander, Terence W.; Premasekharan, Gayatri; Paris, Pamela L.

doi:10.1016/j.pharmthera.2013.12.011

Cited by 78 publications

(63 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there are currently numerous CTC detection methodologies [comprehensive reviews (13, 50–53), the CellSearch system (Veridex, USA)], an immunomagnetic bead capture system based on epithelial cell adhesion molecule (EpCAM), followed by immunofluorescence analysis predominates, as it is the only current method to achieve Federal Drug Administration approval. As malignant cell transcriptional profiles vary, especially during processes such as EMT and CSC formation, expression of identifying proteins may be lost in CTCs as well as being present in non-CTCs, reducing sensitivity and specificity.…”

Section: Ctc Isolation Methodologiesmentioning

confidence: 99%

Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelialâ€“Mesenchymal Plasticity

et al. 2015

View full text Add to dashboard Cite

There is increasing interest in circulating tumor cells (CTCs) due to their purported role in breast cancer metastasis, and their potential as a “liquid biopsy” tool in breast cancer diagnosis and management. There are, however, questions with regards to the reliability and consistency of CTC detection and to the relationship between CTCs and prognosis, which is limiting their clinical utility. There is increasing acceptance that the ability of CTCs to alter from an epithelial to mesenchymal phenotype plays an important role in determining the metastatic potential of these cells. This review examines the phenotypic and genetic variation, which has been reported within CTC populations. Importantly, we discuss how the detection and characterization of CTCs provides additional and often differing information from that obtained from the primary tumor, and how this may be utilized in determining prognosis and treatment options. It has been shown for example that hormone receptor status often differs between the primary tumor and CTCs, which may help to explain failure of endocrine treatment. We examine how CTC status may introduce alternative treatment options and also how they may be used to monitor treatment. Finally, we discuss the most interesting current clinical trials involving CTC analysis and note further research that is required before the breast cancer “liquid biopsy” can be realized.

show abstract

Section: Ctc Isolation Methodologiesmentioning

confidence: 99%

Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelialâ€“Mesenchymal Plasticity

et al. 2015

View full text Add to dashboard Cite

show abstract

“…To confirm these assumptions, two clinical trials are currently underway through the Stand Up to Cancer and the Prostate Cancer Foundations [33]. These studies aim to evaluate the potential for changing levels of CTCs in the blood during therapy to predict disease course among patients with prostate cancer.…”

Section: Prostate Cancermentioning

confidence: 99%

Circulating tumor cells and their clinical significance

Grzybowska

Fabisiewicz²

2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Metastases to other organs and the formation of secondary tumors are responsible for 90% of cancer-related deaths. However, even in the early stages of cancer, about 30-40% of patients with localized disease may have latent metastasis, which are likely derived from circulating tumor cells (CTCs) involved in disease progression. Therefore, detection and analysis of CTCs can play an important role in the diagnosis and decision-making of adjuvant treatment that aims to prevent metastasis. At present, patients' selection of treatment is based on the statistical risk of recurrence of metastatic disease, without considering whether the tumor cells have spread from the primary tumor. This may lead to unnecessary treatment of non-metastatic disease patients. Therefore, early detection of CTCs in the blood is critically important, and should allow for a more accurate assessment of disease severity. Here, we provide an overview of CTC phenotypes, including plasticity of CTCs, and their clinical significance. NOWOTWORY J Oncol 2017; 67, 4: 243-250

show abstract

“…Besides cytokeratins, EpCAM expression is used in the majority of CTC enrichment methods based on antibody-capture [91, 92]. Yet EMT could downregulate this protein and other epithelial proteins, leading to a subpopulation of CTC that will be missed during enrichment or detection.…”

Section: Challenges In Ctc Identificationmentioning

confidence: 99%

Detection of Circulating Tumor Cells

2014

View full text Add to dashboard Cite

The increasing number of treatment options for patients with metastatic carcinomas has created an accompanying need for methods to determine if the tumor will be responsive to the intended therapy and to monitor its effectiveness. Ideally, these methods would be noninvasive and provide quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells shed into the blood during metastasis may satisfy this need. Here we review the CellSearch technology used for the detection of circulating tumor cells and discuss potential future directions for improvements.

show abstract

Looking back, to the future of circulating tumor cells

Cited by 78 publications

References 103 publications

Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelialâ€“Mesenchymal Plasticity

Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelialâ€“Mesenchymal Plasticity

Circulating tumor cells and their clinical significance

Detection of Circulating Tumor Cells

Contact Info

Product

Resources

About